L-carnitine attenuates doxorubicin-induced lipid peroxidation in rats

Free Radical Biology and Medicine

Volumn 26, Issue 9-10, 1999, Pages 1158-1165

  Luo, Xiaoping ^a   Reichetzer, Barbara ^a   Trines, Jean ^b   Benson, Lee N ^b   Lehotay, Denis C ^b  

^a Division of Clinical Pharmacology   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Aldehyde; Carnitine; Doxorubicin; Free radical; Gas chromatography mass spectrometry; Lipid peroxidation

Indexed keywords

CARNITINE; DOXORUBICIN; MYOSIN LIGHT CHAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ECHOCARDIOGRAPHY; ENERGY METABOLISM; GAS CHROMATOGRAPHY; HEART MUSCLE METABOLISM; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT;

ALDEHYDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARNITINE; DOXORUBICIN; ECHOCARDIOGRAPHY; HEART; LIPID PEROXIDATION; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOSIN LIGHT CHAINS; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0032982416     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(98)00303-7     Document Type: Article

References (48)

1. Booser D.J., Hortobagyi G.N. Anthracycline antibiotics in cancer therapy focus on drug resistance. Drugs. 47:1994;223-258.
2. Lown W.J. Anthracycline and anthraquinone anticancer agents current status and recent developments . Pharmacol. Ther. 60:1993;185-214.
3. Muhammed H., Ramasarma T., Kurup C.K. Inhibition of mitochondrial oxidative phosphorylation by adriamycin. Biochim. Biophys. Acta. 722:1982;43-50.
4. Singal P.K., Deally C.M.R., Weinberg L.E. Subcellular effects of adriamycin in the heart a concise review . J. Mol. Cell. Cardiol. 19:1987;817-828.
5. Young R.C., Ozols R.F., Myers C.E. The anthracycline antineoplastic drugs. N. Engl. J. Med. 305:1981;139-153.
6. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324:1991;808-815.
7. Steinherz L.J., Graham T., Hurwitz R., Sondheimer H.M., Schwarz R.G., Sandor G., Benson L., Williams R. Guidelines for cardiac monitoring of children during and after anthracycline therapy report of the Cardiology Committee of the Children's Cancer Study Group . Pediatrics. 89:1992;942-949.
8. Bieber L.L. Carnitine. Ann. Rev. Biochem. 57:1988;261-283.
9. Bremer J. Carnitine-metabolism and function. Physiol. Rev. 63:1983;1420-1480.
10. Siliprandi N., Sartorelli L., Ciman M., Di Lisa F. Carnitine metabolism and clinical chemistry . Clin. Chim. Acta. 183:1989;3-12.
11. Tripp M.E., Katcher M.L., Peters H.A., Gilbert E.F., Arya S., Hodach R.J., Shug A.L. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis a treatable cardiomyopathy . N. Engl. J. Med. 303:1981;385-390.
12. Waber, L. J.; Valle, D.; Neill, C.; Di Mauro, S.; Shug, A. L. Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J. Pediatr. 101:700-705; 1982.
13. Wittels B., Spann J.F. Defective lipid metabolism in the failing heart. J. Clin. Invest. 47:1968;1787-1794.
14. Reznick A.Z., Kagan V.E., Ramsey R., Tsuchiya M., Khwaja S., Serbinova E.A., Packer L. Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperfusion injury the possible role of iron chelation . Arch. Biochem. Biophys. 296:1992;394-401.
15. Singh R.B., Niaz M.A., Agarwal P., Beegun R., Rastogi S.S., Sachan D.S. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad. Med. J. 72:1996;45-50.
16. De Leonardis V., Neri B., Bacalli S., Cinelli P. Reduction of cardiac toxicity of anthracyclines by L-carnitine preliminary overview of clinical data . Int. J. Clin. Pharmacol. Res. 2:1985;137-142.
17. Neri, B.; Cini-Neri, G.; Bartalucci, S.; Bandinelli, M. Protection effect of L-carnitine on cardiac metabolic damage induced by doxorubicin in vitro. Anticancer Res. 6:659-662; 1986.
18. Shug A.L. Protection from adriamycin-induced cardiomyopathy in rats. Z. Kardiol. 76:1987;46-52.
19. Luo X.P., Evrovsky Y., Cole D., Trines J., Benson L.N., Lehotay D.C. Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Biochim. Biophy. Acta. 1360:1997;45-52.
20. Siveski-Iliskovic N., Thomas T.P., Kaul N., Slezak J., Singal P.K., Doxorubin-induced cardiomyopathy: a model of congestive heart failure. In: Nagano M., Takeda N., Dhalla N.S. The Cardiomyopathic heart. 1994;277-283 Raven Press Ltd, New York.
21. Luo X.P., Yazdanpanah M., Bhooi N., Lehotay D.C. Determination of aldehydes and other lipid peroxidation products in biological samples by gas chromatography-mass spectrometry. Anal. Biochem. 228:1995;294-298.
22. Alegria A.E., Samuni A., Mitchell J.B., Riesz P., Russo A. Free radicals induced by adriamycin-sensitive and adriamycin-resistant cells a spin-trapping study . Biochemistry. 28:1989;8653-8658.
23. Thornalley P.J., Dodd N.J.F. Free radical production from normal and adriamycin-treated rat cardiac sarcosomes. Biochem. Pharmacol. 34:1985;669-674.
24. Doroshow J.H., Akman S., Chu F.F., Esworthy S. Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones. Pharmacol. Ther. 47:1990;359-370.
25. 2+ binding and lipid peroxidation but depresses myocardial function. Am. J. Physiol. 250:(Heart Circ. Physiol.):1986;H419-H425.
26. Singal P.K., Siveski-Iliskovic N., Hill M., Thomas T.P., Li T. Combination therapy with Probucol prevents adriamycin-induced cardiomyopathy. J. Mol. Cell. Cardiol. 27:1995;1055-1063.
27. Tong J., Ganguly P.K., Singal P.K. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am. J. Physiol. 260:(Heart Circ. Physiol.):1991;H909-H916.
28. Bruenner B.A., Jones A.D., German J.B. Direct characterization of protein adducts of the lipid peroxidation product 4-hydroxy-2-nonenal using electrospray mass spectrometry. Chem. Res. Toxicol. 8:1995;552-559.
29. Halliwell B. Free radicals, antioxidants, and human disease curiosity, cause, or consequence? Lancet. 344:1994;721-724.
30. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, melondialdehyde and related aldehydes. Free Radic. Biol. Med. 11:1991;81-128.
31. Esterbauer H., Zollner H. Methods for determination of aldehydic lipid peroxidation products. Free Radic. Biol. Med. 7:1989;197-203.
32. Loidl-Stahlhofen A., Spiteller G. Alpha-hydroxyaldehydes, products of lipid peroxidation. Biochim. Biophys. Acta. 1211:1994;156-160.
33. Alary, J.; Bravais, F.; Cravedi, J-P.; Debrauwer, L.; Rao, D.; Bories, G. Mercapturic acid conjugates as urinary end metabolites of the lipid peroxidation product 4-hydroxy-2-nonenal in the rat. Chem. Res. Toxicol. 8:34-39; 1995.
34. Griffin-Green E.A., Zaleska M.M., Erecinska M. Adriamycin-induced lipid peroxidation in mitochondria and microsomes. Biochem. Pharmacol. 37:1988;3071-3077.
35. 7-12 acyloins in the kidney of wistar rats after treatment with a renal carcinogen, ferric nitrilotriacetate. Free Radic. Biol. Med. 22:1997;1019-1027.
36. Toyokuni S., Uchida K., Okamota K., Hattori-Nakakuki Y., Hiai H., Stadtman E.R. Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc. Natl. Acad. Sci. USA. 91:1994;2616-2620.
37. Odom A.L., Hatwig C.A., Stanley J.S., Benson A.M. Biochemical determinants of adriamycin toxicity in mouse liver, heart and intestine. Biochem. Pharmacol. 43:1992;831-836.
38. Isobe M., Nagai R., Takaku F., Yamaguchi T., Yazaki Y. Reduction of myocardial infarct size by early intracoronary thrombolysis as assessed by serum cardiac myosin light chains and left ventricular function. J. Cardiol. 20:1997;521-530.
39. Katus H.A., Diederich K.W., Mehmel H.V., Scheffold T., Schwarz T., Kubler W. Acute myocardial infarct myosin light chain liberation and ventricular function . Klin. Wochenschr. 66:1988;784-789.
40. Isobe M., Nagai R., Yamaoki K., Nakaoka H., Yazaki Y. Quantification of myocardial infarct size after coronary reperfusion by serum cardiac myosin light chain in conscious dogs. Circ. Res. 65:1989;684-694.
41. Wang J.X., Shi Q.W., Wu T.W., Jackowski G., Mickle D.A. The quantitation of human ventricular myosin light chain-1 in serum after myocardial necrosis and infarction. Clin. Chim. Acta. 181:1989;325-335.
42. Schmitt K., Tulzer G., Merl M., Aichhorn G., Grillenberger A., Wiesinger G., Hofstadler G. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography diastolic versus systolic parameters . Eur. J. Pediatr. 154:1995;201-204.
43. Ewer M.S., Benjamin R.S., Prevention of cardiac damage due to adriamycin: modification of administration. In: Bricker J.T., Green D.M., D'Angio G.J. Cardiac toxicity after treatment for childhood cancer. 1994;109-114 Wiley-Liss Inc, New York.
44. Steinherz, L. J.; Steinherz, P. G.; Heller, G. Anthracycline-related cardiac damage. In: Bricker, J. T.; Green, D. M.; D'Angio, G. J., eds. Cardiac toxicity after treatment for childhood cancer. New York: Wiley-Liss Inc; 1994:63-72.
45. De Leonardis V., De Scalzi M., Neri B., Bartalucci S., Cinelli P. Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens. Int. J. Clin. Pharm. Res. 7:1987;307-311.
46. Mortensen S.A., Aabo K., Jonsson T., Baandrup U. Clinical and non-invasive assessment of anthracycline cardiotoxicity perspectives on myocardial protection . Int. J. Clin. Pharm. Res. 6:1986;137-150.
47. Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 261:1986;3060-3067.
48. Arduini A., Fernandez E., Pallini R., Mancinelli G., Di Toppi G.S., Belfiglio M., Scurti R., Federici G. Effect of propionyl-L-carnitine on rat spinal cord ischaemia and post-ischaemic reperfusion injury. Free Radic. Res. Comm. 10:1990;325-332.